3 horrendous healthcare stocks this week 3-28-14
out of 10
Post on 22-Aug-2014
Embed Size (px)
DESCRIPTIONThis week's most horrendous healthcare stocks.
- 3 Horrendous Health-Care Stocks This Week
- Has the so-called biotech bubble burst? Two of this weeks most horrendous health-care stocks bolster the theory, while the third stock could simply be experiencing the effects of market gravity. Source: Wikimedia Commons
- The biotechs shares plunged more than 46% for the week. Exelixis (Nasdaq: EXEL) Source: Yahoo! Finance
- It announced on Tuesday the completion of an interim analysis of Cometriq and that the phase 3 prostate cancer trial would continue to final analysis. Many observers expected the study would be stopped early, as Johnson & Johnsons Zytiga and Medivations Xtandi were. Exelexis expects top-line data from the phase 3 study later this year. Why Exelixis got clobbered
- Shares of the cloud-based health-care technology company dropped 27% this week. Castlight Health (NYSE: CSLT) Source: Yahoo! Finance
- Castlights IPO was last week, with the stock vaulting nearly 150% on its first day of trading. With only $13 million in revenue, Castlights market cap hit $3 billion. The backlash is apparently now under way, with plenty of critics. Yahoo! Finance called Castlight the most overpriced IPO of the century. Why Castlights stock careened
- The stock of the biopharmaceutical company fell 24% this week. Galena Biopharma (Nasdaq: GALE) Source: Yahoo! Finance
- This weeks decline appears to be a continuation from last weeks announcement of an SEC investigation. The investigation stems from alleged questionable stock-promotions efforts by The DreamTeam Group, particularly involving the posting of positive articles about Galena. Several online financial sites, including The Motley Fool, pulled articles related to the controversy over the past few months. Why Galena shares dropped
- While Castlights business model is compelling, the stock really is overpriced right now. Galena could certainly come back with good news from cancer immunotherapy Neuvax. Exelixis gets the nod as the most likely to rebound. Continuation of the Cometriq study was disappointing, but the market overreacted, in my view. Best shot at bouncing back?
- Find out which stock The Motley Fools chief investment officer selected as the top pick for 2014 in our free report!
View more >